Published in Arch Intern Med on April 24, 2000
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis (2004) 1.94
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 1.92
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study. Lancet HIV (2015) 1.38
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) project. Arch Pediatr Adolesc Med (2009) 1.03
Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. J Biol Chem (2013) 1.02
Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine (2009) 1.01
The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Med Decis Making (2008) 0.87
Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009. Health Aff (Millwood) (2014) 0.85
Patient factors impacting antiretroviral drug adherence in a Nigerian tertiary hospital. J Pharmacol Pharmacother (2012) 0.84
Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)? Eur J Epidemiol (2004) 0.82
Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis? Arch Pathol Lab Med (2003) 0.77
Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort. Immunol Lett (2014) 0.75
Virologic and Immunologic Response to Highly Active Antiretroviral Therapy. Curr Infect Dis Rep (2002) 0.75
The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med (2001) 37.70
Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ (2001) 20.65
The hazards of scoring the quality of clinical trials for meta-analysis. JAMA (1999) 17.00
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol (2001) 12.72
Misleading meta-analysis. BMJ (1995) 11.94
Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol (2000) 7.95
Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ (2001) 7.13
Who benefits from medical interventions? BMJ (1994) 5.58
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ (2001) 4.47
Socioeconomic differentials in wealth and health. BMJ (1993) 4.32
Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med (2000) 3.77
Magnesium and myocardial infarction. Lancet (1994) 3.74
Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev (2007) 3.51
HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis (2005) 3.49
Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ (1998) 3.37
Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis (1982) 3.36
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess (2001) 3.32
Smoking and health promotion in Nazi Germany. J Epidemiol Community Health (1994) 3.20
Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS (1999) 3.04
Do all men attending departments of genitourinary medicine need to be screened for non-gonococcal urethritis? Int J STD AIDS (2002) 2.81
Funding clinical research. Lancet (1999) 2.63
Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis (1990) 2.52
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess (2005) 2.38
The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed (1994) 2.38
Genital Chlamydia trachomatis infections in Uppsala County, Sweden, 1985-1993: declining rates for how much longer? Sex Transm Dis (1995) 2.36
Commentary: understanding it all--health, meta-theories, and mortality trends. BMJ (1997) 2.35
Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev (2003) 2.32
Health problems after travel to developing countries. J Infect Dis (1987) 2.31
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
Are randomised controlled trials in the BMJ different? BMJ (2001) 2.26
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis (2001) 2.24
Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess (2007) 2.23
Impact of the regulatory loci agr, sarA and sae of Staphylococcus aureus on the induction of alpha-toxin during device-related infection resolved by direct quantitative transcript analysis. Mol Microbiol (2001) 2.20
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis (2011) 2.15
Hip fractures and fluoridation in Utah's elderly population. JAMA (1992) 2.13
Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest (1984) 2.11
Immobilized proteins in buffer imaged at molecular resolution by atomic force microscopy. Biophys J (1990) 2.04
Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med (2008) 2.03
Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science (1995) 2.01
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
Spinal epidural abscess in clinical practice. QJM (2007) 2.00
Role of Mycoplasma genitalium and Ureaplasma urealyticum in acute and chronic nongonococcal urethritis. Clin Infect Dis (2001) 1.89
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med (2001) 1.88
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer (2010) 1.86
Smoking and death. Public health measures were taken more than 40 years ago. BMJ (1995) 1.85
Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J (2010) 1.83
The chlamydia screening studies: rationale and design. Sex Transm Infect (2004) 1.83
Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. Clin Infect Dis (1999) 1.82
Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis (1992) 1.81
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med (2012) 1.76
Socioeconomic differences in mortality in Britain and the United States. Am J Public Health (1992) 1.71
Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS (1999) 1.70
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer (2008) 1.70
Meta-analysis. Unresolved issues and future developments. BMJ (1998) 1.69
The role of diabetes mellitus in patients with bloodstream infections. Swiss Med Wkly (2008) 1.69
Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clin Microbiol Infect (2006) 1.66
Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart (2005) 1.61
Incommunicable knowledge? Interpreting and applying the results of clinical trials and meta-analyses. J Clin Epidemiol (1998) 1.60
Erythema of the proximal nailfold in HIV-infected patients. J Am Acad Dermatol (1996) 1.59
Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study. Sex Transm Infect (2006) 1.59
Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection (2004) 1.58
Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun (1996) 1.57
Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J (2010) 1.57
A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS (2001) 1.56
Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon. J Virol (1994) 1.56
Calcium signalling in cardiac muscle: refractoriness revealed by coherent activation. Nat Cell Biol (1999) 1.54
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart (2003) 1.53
Prospective endoscopic study of stress erosions and ulcers in critically ill neurosurgical patients: current incidence and effect of acid-reducing prophylaxis. Crit Care Med (1990) 1.52
Physical activity assessment using a pedometer and its comparison with a questionnaire in a large population survey. Am J Epidemiol (1995) 1.50
In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother (1995) 1.50
Meta-analysis. Beyond the grand mean? BMJ (1997) 1.48
Rash with amoxycillin-clavulanate therapy in HIV-infected patients. Lancet (1989) 1.47
[The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. Internist (Berl) (2008) 1.47
Human versus porcine insulin gone wrong. Diabetes Care (1992) 1.44
Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother (1991) 1.44
Hepatitis B vaccination of high-risk individuals in the canton of Zurich. Eur J Clin Microbiol (1983) 1.43
Misleading meta-analysis. BMJ (1995) 1.43
Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis (1995) 1.43
Incidence and spectrum of severe medical complications among hospitalized HIV-seronegative and HIV-seropositive narcotic drug users. AIDS (1996) 1.42
Exudation primes human and guinea pig neutrophils for subsequent responsiveness to the chemotactic peptide N-formylmethionylleucylphenylalanine and increases complement component C3bi receptor expression. J Clin Invest (1986) 1.41
Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer (2012) 1.41